Amylyx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMLX)

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price objectives for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $40.00 to $50.00. On average, they anticipate the company's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.

Amylyx Pharmaceuticals' stock was trading at $36.95 on January 1st, 2023. Since then, AMLX stock has decreased by 61.7% and is now trading at $14.16.
View the best growth stocks for 2023 here.

Amylyx Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 7,070,000 shares, a decrease of 10.8% from the October 31st total of 7,930,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.2% of the company's shares are sold short.
View Amylyx Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our AMLX earnings forecast.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Monday, March, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The company earned $21.89 million during the quarter, compared to analysts' expectations of $3.05 million. Amylyx Pharmaceuticals had a net margin of 0.62% and a trailing twelve-month return on equity of 0.49%.

Amylyx Pharmaceuticals (NASDAQ:AMLX) pays an annual dividend of $1.02 per share and currently has a dividend yield of 0.00%.

ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE).

(AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (3.73%), Avidity Partners Management LP (2.60%), Adage Capital Partners GP L.L.C. (2.52%), Morgan Stanley (1.41%), Emerald Advisers LLC (1.24%) and Emerald Mutual Fund Advisers Trust (1.01%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends.

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.